REAL-WORLD EFFECTIVENESS AND SAFETY OF RANIBIZUMAB TREATMENT IN PATIENTS WITH AND WITHOUT POLYPOIDAL CHOROIDAL VASCULOPATHY
Authors:
- Adrian KohAKAdrian Koh
- on behalf of the LUMINOUS study steering committeeOCon behalf of the LUMINOUS study steering committee
Open Access
- 1 August 2020
- journal article
- research article
- Published by Wolters Kluwer Health in Retina
- Vol. 40 (8) , 1529-1539
Abstract
Purpose: To evaluate the real-world effectiveness and safety of intravitreal ranibizumab 0.5 mg in treatment-naive patients with and without polypoidal choroidal vasculopathy (PCV). Methods: Assessment of neovascular age-related macular degeneration patients with or without PCV after 12 months of ranibizumab treatment during the LUMINOUS study. Outcome measures were visual acuity and central retinal thickness changes from baseline and the rate of ocular adverse events. Results: At baseline, 572 and 5,644 patients were diagnosed with and without PCV, respectively. The mean visual acuity gain from baseline at Month 12 in the PCV and non-PCV groups was +5.0 and +3.0 letters, respectively; these gains were achieved with a mean of 4.4 and 5.1 ranibizumab injections. Eighty percent of PCV patients and 72.2% of non-PCV patients who had baseline visual acuity ≥73 letters maintained this level of vision at Month 12; 20.6% and 17.9% of patients with baseline visual acuity <73 letters achieved visual acuity ≥73 letters in these groups. Greater reductions in central retinal thickness from baseline were also observed for the PCV group versus the non-PCV group. The rate of serious ocular adverse events was 0.7% (PCV group) and 0.9% (non-PCV group). Conclusion: LUMINOUS confirms the effectiveness and safety of ranibizumab in treatment-naive patients with PCV.Keywords
This publication has 38 references indexed in Scilit:
- Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programmeBritish Journal of Ophthalmology, 2013
- EVEREST STUDYRetina, 2012
- POLYPOIDAL CHOROIDAL VASCULOPATHYRetina, 2012
- Outcome of ranibizumab treatment in neovascular age related macula degeneration in eyes with baseline visual acuity better than 6/12Eye, 2011
- Do We Need a New Classification for Choroidal Neovascularization in Age-Related Macular Degeneration?Retina, 2010
- Polypoidal choroidal vasculopathy with an appearance similar to classic choroidal neovascularisation on fluorescein angiographyBritish Journal of Ophthalmology, 2007
- Ranibizumab versus Verteporfin for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- INDOCYANINE GREEN VIDEOANGIOGRAPHY OF IDIOPATHIC POLYPOIDAL CHOROIDAL VASCULOPATHYRetina, 1995
- IDIOPATHIC POLYPOIDAL CHOROIDAL VASCULOPATHY (IPCV)Retina, 1990